Colorado-based drug discovery and developer OnKure Therapeutics raised USD 54 million in a Series C funding round led by Surveyor Capital, with participation from Deep Track Capital, Acorn Bioventures, Cormorant Asset Management, Perceptive Advisors, Samsara BioCapital, BlackRock, and other undisclosed investors. This brings the total funds raised to USD 121.5 million.
The funds will be used to support the development of OnKure's pipeline of precision medicines, including advancing its lead discovery program, OKI-219, into clinical development.
OnKure is a clinical-stage biopharmaceutical company focused on developing precise medicines that target specific drivers of cancer using a structure-based drug design approach. OnKure's pipeline includes tumor-agnostic drug candidates, aiming to maximize effectiveness and safety. It is currently developing bocodepsin (OKI-179), an oral inhibitor for hematological and solid tumors, and OKI-219, a selective inhibitor for PI3K alpha H1047R.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.